Bristol-Myers Squibb CompanyJuly 30, 2012

FDA 483 - Bristol-Myers Squibb Company - July 30, 2012

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bristol-Myers Squibb Company

Record Details

An FDA inspection of Celgene Corporation's Summit, NJ facility revealed two significant issues. The firm failed to thoroughly review unexplained discrepancies, specifically concerning an off-white appearance defect in Azacitidine for Injection lots. Additionally, there was no written program for assessing drug product stability, and numerous Revlimid Capsule stability samples were not properly logged into stability chambers.

Company: Bristol-Myers Squibb Company
Inspection Date: July 30, 2012
Product Type: Drugs
Office: New Jersey District Office
People: Jose M. Cayuela
Justine C. Tomasso

Open in Dashboard

ID · 10c364b5-0a3f-4a9c-9052-a72355ca9483